Pharvaris: An April 2027 Decision Could Double the Addressable Market for deucrictibant

April 2027 matters because the market case may extend beyond one approval

The clock is already running

The key setup is not only whether deucrictibant wins on-demand approval. It is whether April 2027 becomes the point where investors see that the market could be bigger than a single on-demand launch. Pharvaris has an NDA accepted for on-demand treatment, with a PDUFA target action date of April 23, 2027. The more important near-term question is whether the prophylaxis program develops in time to change that narrative. Pharvaris has pointed to a prophylaxis NDA dossier... filing in 1H2026, while CHAPTER-3 topline data are anticipated later. If prevention de-risks before the 2027 decision, the opportunity could start looking broader than a single indication.

What deucrictibant is trying to do

HAE attacks are driven by excess bradykinin, which makes blood vessels leaky and triggers painful swelling. Deucrictibant is an oral bradykinin B2 receptor antagonist, and Pharvaris is aiming at both prevention and treatment. If one molecule can credibly cover both ends of the care pathway, the addressable use case becomes materially larger.

Why the sequence matters more than the final date

A narrow view treats this as a single-binary approval story. The more interesting setup is staged: if the prophylaxis program progresses ahead of the 2027 decision, April 2027 may matter less as a go/no-go moment and more as a point when investors begin valuing a wider market.

Why one molecule could cover both sides of HAE care

One molecule, two formulations

The important distinction is not just mechanism. It is formulation. Pharvaris is building deucrictibant around two formulations: an immediate-release capsule for on-demand use and an extended-release tablet for prevention. That matters because HAE management is not only about responding to attacks. It also includes reducing their frequency and day-to-day burden.

For on-demand therapy, the regulatory case already has substance. The NDA cites data showing rapid relief, sustained response to resolution of HAE attack symptoms, and a well-tolerated safety profile. In practical terms, that supports the case for an oral rescue option rather than only another preventive therapy.

Why prevention could expand the commercial case

Prevention is where the market could expand. CHAPTER-3 is the pivotal Phase 3 study for prophylaxis, using an extended-release tablet, with topline data anticipated in 3Q2026. That is the main catalyst to watch.

Current HAE management still divides care into separate buckets: prevent occurrence of angioedema attacks or treat manifestations of attacks when they occur, and some people with HAE continue to have unmet needs for both prevention and treatment. If deucrictibant can address both, it would no longer be only an add-on rescue therapy; it could become a fuller treatment option across the care pathway.

AAE-C1INH is still optionality, not the core thesis

There is also upside beyond classic HAE. Pharvaris has said it intends to pursue development in acquired angioedema due to C1-inhibitor deficiency, and the ongoing CREAATE study is enrolling for prophylactic and on-demand treatment in that population. That is optionality, not proof. But if deucrictibant later shows promise in AAE-C1INH, April 2027 may look less like the main event and more like the first step.

What investors should actually watch before 2027

Execution and funding are the real signals

The most important signal is not the volume of announcements. It is whether Pharvaris keeps the development sequence on track long enough for the market to reprice the story before the April 2027 decision. The company reported €247 million in cash and cash equivalents at end-Q1, and a subsequent $132 million underwritten offering extends its runway into 2028. That gives management time to advance the program, but only if execution stays disciplined through the next filings and readouts.

Catalysts and what could break the thesis

Near-term catalysts - A clean NDA filing in 1H2026 would support regulatory progress and show the on-demand program is formulation-ready. - CHAPTER-3 topline data in 3Q2026 is the hinge. Strong prevention results would be the clearest path to broadening the story beyond on-demand use. - A smooth path to the April 23, 2027 PDUFA date matters most if the earlier steps land well.

What could break the thesis - Filing slips past 1H2026 or the data package appears less compelling than expected. - CHAPTER-3 is delayed or the prophylaxis readout does not clearly de-risk expansion beyond on-demand use. - Funding pressure returns despite the recent raise, shifting focus back to dilution risk. - AAE-C1INH remains a watchpoint rather than a core catalyst unless the main HAE sequence stays on track.

The setup is staged, not binary

This is not just a blind bet on April 2027. It is a staged catalyst story. The more attractive setup is to watch for disciplined execution through filing and readout, then see whether the stock begins to reflect a wider addressable market rather than only a single on-demand approval.